Antipsychotic polypharmacy

A Japanese survey of prescribers' attitudes and rationales

Taishiro Kishimoto, Koichiro Watanabe, Hiroyuki Uchida, Masaru Mimura, John M. Kane, Christoph U. Correll

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

While combining antipsychotics is common in schizophrenia treatment, the literature on the reasons for antipsychotic polypharmacy (APP) is limited. We aimed to identify prescriber attitudes and rationales for APP in Japan where high APP utilization is reported. Two-hundred and seventeen psychiatrists participated in the survey, which assessed APP attitudes and behaviors. Prescribing APP to 47.7±24.7% (mean±S.D.) of their patients, psychiatrists reported that they were "moderately" concerned about APP. The most APP-justifiable factors were (1="not at all" to 5="extreme") cross titration (4.50±0.67), randomized controlled evidence (3.67±0.83), and treatment of comorbid conditions (3.31±0.83). Conversely, APP-discouraging factors were chronic side effects (4.14±0.64), difficulty determining cause and effect (4.07±0.74), and acute side effects (3.99±0.81). Comparing high to low APP prescribers (>50% vs. ≤50% of patients), no differences emerged regarding APP justification and concerns. In multivariate analyses, high APP use was associated with practice at a psychiatric hospital (OR: 2.70, 95% CI: 1.29-5.67, p=0.009), concern about potential drug-drug interactions (OR: 1.56, 95% CI: 1.04-2.35, p=0.031), and less reliance on case reports of APP showing efficacy (OR: 0.64, 95% CI: 0.44-0.92, p=0.017) (r2=0.111, p=0.001). High and low APP prescribers shared a comparable degree of justifications and concerns. Future research should examine the impact of cultural determinants on APP.

Original languageEnglish
Pages (from-to)406-411
Number of pages6
JournalPsychiatry Research
Volume209
Issue number3
DOIs
Publication statusPublished - 2013 Oct 30

Fingerprint

Polypharmacy
Antipsychotic Agents
Surveys and Questionnaires
Psychiatry
Psychiatric Hospitals
Drug Interactions

Keywords

  • Antipsychotic combination therapy
  • Attitudes
  • Concerns
  • Polypharmacy
  • Schizophrenia
  • Survey

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Antipsychotic polypharmacy : A Japanese survey of prescribers' attitudes and rationales. / Kishimoto, Taishiro; Watanabe, Koichiro; Uchida, Hiroyuki; Mimura, Masaru; Kane, John M.; Correll, Christoph U.

In: Psychiatry Research, Vol. 209, No. 3, 30.10.2013, p. 406-411.

Research output: Contribution to journalArticle

Kishimoto, Taishiro ; Watanabe, Koichiro ; Uchida, Hiroyuki ; Mimura, Masaru ; Kane, John M. ; Correll, Christoph U. / Antipsychotic polypharmacy : A Japanese survey of prescribers' attitudes and rationales. In: Psychiatry Research. 2013 ; Vol. 209, No. 3. pp. 406-411.
@article{2443cd7fc9964dc59e4b94899ea95c47,
title = "Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales",
abstract = "While combining antipsychotics is common in schizophrenia treatment, the literature on the reasons for antipsychotic polypharmacy (APP) is limited. We aimed to identify prescriber attitudes and rationales for APP in Japan where high APP utilization is reported. Two-hundred and seventeen psychiatrists participated in the survey, which assessed APP attitudes and behaviors. Prescribing APP to 47.7±24.7{\%} (mean±S.D.) of their patients, psychiatrists reported that they were {"}moderately{"} concerned about APP. The most APP-justifiable factors were (1={"}not at all{"} to 5={"}extreme{"}) cross titration (4.50±0.67), randomized controlled evidence (3.67±0.83), and treatment of comorbid conditions (3.31±0.83). Conversely, APP-discouraging factors were chronic side effects (4.14±0.64), difficulty determining cause and effect (4.07±0.74), and acute side effects (3.99±0.81). Comparing high to low APP prescribers (>50{\%} vs. ≤50{\%} of patients), no differences emerged regarding APP justification and concerns. In multivariate analyses, high APP use was associated with practice at a psychiatric hospital (OR: 2.70, 95{\%} CI: 1.29-5.67, p=0.009), concern about potential drug-drug interactions (OR: 1.56, 95{\%} CI: 1.04-2.35, p=0.031), and less reliance on case reports of APP showing efficacy (OR: 0.64, 95{\%} CI: 0.44-0.92, p=0.017) (r2=0.111, p=0.001). High and low APP prescribers shared a comparable degree of justifications and concerns. Future research should examine the impact of cultural determinants on APP.",
keywords = "Antipsychotic combination therapy, Attitudes, Concerns, Polypharmacy, Schizophrenia, Survey",
author = "Taishiro Kishimoto and Koichiro Watanabe and Hiroyuki Uchida and Masaru Mimura and Kane, {John M.} and Correll, {Christoph U.}",
year = "2013",
month = "10",
day = "30",
doi = "10.1016/j.psychres.2013.03.014",
language = "English",
volume = "209",
pages = "406--411",
journal = "Psychiatry Research",
issn = "0165-1781",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Antipsychotic polypharmacy

T2 - A Japanese survey of prescribers' attitudes and rationales

AU - Kishimoto, Taishiro

AU - Watanabe, Koichiro

AU - Uchida, Hiroyuki

AU - Mimura, Masaru

AU - Kane, John M.

AU - Correll, Christoph U.

PY - 2013/10/30

Y1 - 2013/10/30

N2 - While combining antipsychotics is common in schizophrenia treatment, the literature on the reasons for antipsychotic polypharmacy (APP) is limited. We aimed to identify prescriber attitudes and rationales for APP in Japan where high APP utilization is reported. Two-hundred and seventeen psychiatrists participated in the survey, which assessed APP attitudes and behaviors. Prescribing APP to 47.7±24.7% (mean±S.D.) of their patients, psychiatrists reported that they were "moderately" concerned about APP. The most APP-justifiable factors were (1="not at all" to 5="extreme") cross titration (4.50±0.67), randomized controlled evidence (3.67±0.83), and treatment of comorbid conditions (3.31±0.83). Conversely, APP-discouraging factors were chronic side effects (4.14±0.64), difficulty determining cause and effect (4.07±0.74), and acute side effects (3.99±0.81). Comparing high to low APP prescribers (>50% vs. ≤50% of patients), no differences emerged regarding APP justification and concerns. In multivariate analyses, high APP use was associated with practice at a psychiatric hospital (OR: 2.70, 95% CI: 1.29-5.67, p=0.009), concern about potential drug-drug interactions (OR: 1.56, 95% CI: 1.04-2.35, p=0.031), and less reliance on case reports of APP showing efficacy (OR: 0.64, 95% CI: 0.44-0.92, p=0.017) (r2=0.111, p=0.001). High and low APP prescribers shared a comparable degree of justifications and concerns. Future research should examine the impact of cultural determinants on APP.

AB - While combining antipsychotics is common in schizophrenia treatment, the literature on the reasons for antipsychotic polypharmacy (APP) is limited. We aimed to identify prescriber attitudes and rationales for APP in Japan where high APP utilization is reported. Two-hundred and seventeen psychiatrists participated in the survey, which assessed APP attitudes and behaviors. Prescribing APP to 47.7±24.7% (mean±S.D.) of their patients, psychiatrists reported that they were "moderately" concerned about APP. The most APP-justifiable factors were (1="not at all" to 5="extreme") cross titration (4.50±0.67), randomized controlled evidence (3.67±0.83), and treatment of comorbid conditions (3.31±0.83). Conversely, APP-discouraging factors were chronic side effects (4.14±0.64), difficulty determining cause and effect (4.07±0.74), and acute side effects (3.99±0.81). Comparing high to low APP prescribers (>50% vs. ≤50% of patients), no differences emerged regarding APP justification and concerns. In multivariate analyses, high APP use was associated with practice at a psychiatric hospital (OR: 2.70, 95% CI: 1.29-5.67, p=0.009), concern about potential drug-drug interactions (OR: 1.56, 95% CI: 1.04-2.35, p=0.031), and less reliance on case reports of APP showing efficacy (OR: 0.64, 95% CI: 0.44-0.92, p=0.017) (r2=0.111, p=0.001). High and low APP prescribers shared a comparable degree of justifications and concerns. Future research should examine the impact of cultural determinants on APP.

KW - Antipsychotic combination therapy

KW - Attitudes

KW - Concerns

KW - Polypharmacy

KW - Schizophrenia

KW - Survey

UR - http://www.scopus.com/inward/record.url?scp=84885476215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885476215&partnerID=8YFLogxK

U2 - 10.1016/j.psychres.2013.03.014

DO - 10.1016/j.psychres.2013.03.014

M3 - Article

VL - 209

SP - 406

EP - 411

JO - Psychiatry Research

JF - Psychiatry Research

SN - 0165-1781

IS - 3

ER -